Nature Communications (May 2018)
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models
- Samuel Y. Ng,
- Noriaki Yoshida,
- Amanda L. Christie,
- Mahmoud Ghandi,
- Neekesh V. Dharia,
- Joshua Dempster,
- Mark Murakami,
- Kay Shigemori,
- Sara N. Morrow,
- Alexandria Van Scoyk,
- Nicolas A. Cordero,
- Kristen E. Stevenson,
- Maneka Puligandla,
- Brian Haas,
- Christopher Lo,
- Robin Meyers,
- Galen Gao,
- Andrew Cherniack,
- Abner Louissaint,
- Valentina Nardi,
- Aaron R. Thorner,
- Henry Long,
- Xintao Qiu,
- Elizabeth A. Morgan,
- David M. Dorfman,
- Danilo Fiore,
- Julie Jang,
- Alan L. Epstein,
- Ahmet Dogan,
- Yanming Zhang,
- Steven M. Horwitz,
- Eric D. Jacobsen,
- Solimar Santiago,
- Jian-Guo Ren,
- Vincent Guerlavais,
- D. Allen Annis,
- Manuel Aivado,
- Mansoor N. Saleh,
- Amitkumar Mehta,
- Aviad Tsherniak,
- David Root,
- Francisca Vazquez,
- William C. Hahn,
- Giorgio Inghirami,
- Jon C. Aster,
- David M. Weinstock,
- Raphael Koch
Affiliations
- Samuel Y. Ng
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Noriaki Yoshida
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Amanda L. Christie
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Mahmoud Ghandi
- Broad Institute of Harvard and MIT
- Neekesh V. Dharia
- Broad Institute of Harvard and MIT
- Joshua Dempster
- Broad Institute of Harvard and MIT
- Mark Murakami
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Kay Shigemori
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Sara N. Morrow
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Alexandria Van Scoyk
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Nicolas A. Cordero
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Kristen E. Stevenson
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute
- Maneka Puligandla
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute
- Brian Haas
- Broad Institute of Harvard and MIT
- Christopher Lo
- Broad Institute of Harvard and MIT
- Robin Meyers
- Broad Institute of Harvard and MIT
- Galen Gao
- Broad Institute of Harvard and MIT
- Andrew Cherniack
- Broad Institute of Harvard and MIT
- Abner Louissaint
- Harvard Medical School
- Valentina Nardi
- Harvard Medical School
- Aaron R. Thorner
- Center for Cancer Genome Discovery, Dana-Farber Cancer Institute
- Henry Long
- Center for Functional Epigenetics, Dana-Farber Cancer Institute
- Xintao Qiu
- Center for Functional Epigenetics, Dana-Farber Cancer Institute
- Elizabeth A. Morgan
- Harvard Medical School
- David M. Dorfman
- Harvard Medical School
- Danilo Fiore
- Department of Pathology, Weill Cornell Medical College
- Julie Jang
- Department of Pathology, Keck School of Medicine, University of Southern California
- Alan L. Epstein
- Department of Pathology, Keck School of Medicine, University of Southern California
- Ahmet Dogan
- Department of Pathology, Memorial Sloan-Kettering Cancer Center
- Yanming Zhang
- Department of Pathology, Memorial Sloan-Kettering Cancer Center
- Steven M. Horwitz
- Department of Medicine, Memorial Sloan-Kettering Cancer Center
- Eric D. Jacobsen
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Solimar Santiago
- Aileron Therapeutics Inc
- Jian-Guo Ren
- Aileron Therapeutics Inc
- Vincent Guerlavais
- Aileron Therapeutics Inc
- D. Allen Annis
- Aileron Therapeutics Inc
- Manuel Aivado
- Aileron Therapeutics Inc
- Mansoor N. Saleh
- University of Alabama-Birmingham Comprehensive Cancer Center
- Amitkumar Mehta
- University of Alabama-Birmingham Comprehensive Cancer Center
- Aviad Tsherniak
- Broad Institute of Harvard and MIT
- David Root
- Broad Institute of Harvard and MIT
- Francisca Vazquez
- Broad Institute of Harvard and MIT
- William C. Hahn
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Giorgio Inghirami
- Department of Pathology, Weill Cornell Medical College
- Jon C. Aster
- Harvard Medical School
- David M. Weinstock
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Raphael Koch
- Department of Medical Oncology, Dana-Farber Cancer Institute
- DOI
- https://doi.org/10.1038/s41467-018-04356-9
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 11
Abstract
T- and NK-cell lymphomas (TCL) are a group of lymphoid malignancies characterized by poor prognosis, but the absence of appropriate pre-clinical models has hampered the development of effective therapies. Here the authors establish several pre-clinical models and identify vulnerabilities that could be further exploited to treat patients afflicted by these diseases.
